Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5185022 | 0.91 | LTA4H (0.49) | MAPK8EPHX1CA2NLRP3EPHX2 | |
| SCHEMBL1718743 | 0.85 | TP53 (0.46) | MAPK8EPHX1CA2 | |
| SCHEMBL378766 | 0.83 | EPHX2 (0.54) | MAPK8EPHX1CA2NLRP3EPHX2 | |
| SCHEMBL6869972 | 0.82 | MAPK8 (0.59) | MAPK8EPHX1CA2NLRP3EPHX2 | |
| SCHEMBL5723863 | 0.82 | EPHX1 (0.50) | MAPK8EPHX1EPHX2LTA4H | |
| Hydrochloric Acid SCHEMBL1373117 | 0.81 | EPHX2 (0.52) | MAPK8EPHX1CA2NLRP3EPHX2 | |
| SCHEMBL1462002 | 0.81 | NLRP3 (0.50) | MAPK8EPHX1NLRP3EPHX2LTA4H | |
| SCHEMBL7983265 | 0.81 | POLB (0.56) | MAPK8EPHX1NLRP3EPHX2LTA4H | |
| SCHEMBL11218545 | 0.81 | CA2 (0.52) | CA2 | |
| SCHEMBL28247857 | 0.81 | MAPT (0.49) | MAPK8EPHX1NLRP3EPHX2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0866793-B1 | NITROIMIDAZOLE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF | CHIRON CORP (US) | 2004-10-27 | — | — | EP | claimed |
| US-6087358-A | BACTERICIDES TREATING PATHOGENIC INFECTIONS OF MYCOBACTERIA, CLOSTRIDIUM, CRYPTOSPORIDIUM OR HELICOBACTER AND MULTIDRUG-RESISTANT TUBERCULOSIS | PATHOGENESIS CORPORATION (US) | 2000-07-11 | — | — | US | claimed |
| WO-2025054339-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT | ARCUS BIOSCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-12-26 | — | — | US | disclosed |
| CN-116789670-A | Selective CSF1R inhibitor and application thereof | 中国科学院合肥物质科学研究院 | 2023-09-22 | — | — | CN | disclosed |
| WO-2023173480-A1 | SELECTIVE CSF1R INHIBITOR AND USE THEREOF | 中国科学院合肥物质科学研究院 | 2023-09-21 | — | — | WO | disclosed |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| CN-109803956-A | Novel benzamide compounds, preparation method and acaricide | 杀虫剂(印度)有限公司 | 2019-05-24 | — | — | CN | disclosed |
| CN-108689942-A | Nitrogenous dicyclic compound and its preparation method and application | 广东东阳光药业有限公司 | 2018-10-23 | — | — | CN | disclosed |
| US-10034872-B2 | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | CELGENE CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
| US-9642847-B2 | Combinational compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| EP-0866793-B1 | NITROIMIDAZOLE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF | CHIRON CORP (US) | 2004-10-27 | — | — | EP | disclosed |
| US-6087358-A | BACTERICIDES TREATING PATHOGENIC INFECTIONS OF MYCOBACTERIA, CLOSTRIDIUM, CRYPTOSPORIDIUM OR HELICOBACTER AND MULTIDRUG-RESISTANT TUBERCULOSIS | PATHOGENESIS CORPORATION (US) | 2000-07-11 | — | — | US | disclosed |
| EP-0866793-A4 | — | — | 1998-10-07 | — | — | EP | disclosed |
| EP-0866793-A1 | NITROIMIDAZOLE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF | PATHOGENESIS CORPORATION (US) | 1998-09-30 | — | — | EP | disclosed |
| WO-1997001562-A1 | NITROIMIDAZOLE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF | PATHOGENESIS CORPORATION (US) | 1997-01-16 | — | — | WO | disclosed |
| US-4822903-A | Fluorinated silica catalyst and preparation of aromatic/aliphatic nitriles in the presence thereof | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1989-04-18 | — | — | US | disclosed |
| US-4504595-A | Fluorinated silica catalyst and preparation of aromatic/aliphatic nitriles in the presence thereof | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1985-03-12 | — | — | US | disclosed |
| US-4438042-A | FROM AMIDES, FLUORINATE SILCEOUS CATALYSTS | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-03-20 | — | — | US | disclosed |
| US-4436669-A | CYANATION, DECARBONYLATION, ACID CATALYSTS | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | KCNJ11, KCNJ1, KCNJ8 | MAPK8 1712/4885EPHX1 2050/4885CA2 733/4885 |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | KCNJ11, KCNJ1, KCNJ8 | MAPK8 1712/4885EPHX1 2050/4885CA2 733/4885 |
| US-10034872-B2 | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | CHP1, MCL1, CSGALNACT1 | MAPK8 1966/4885EPHX1 4258/4885CA2 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.